Michael J. Carson is President & VP at Nuvectis Pharma, Inc. (NVCT). They have made 1 open-market trade across 1 company since 2024, most recently 2026-08-03.
CIK 0001896079
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NVCT | 230,118 | $4.2M |
Shares reported on the most recent Form 4, priced at the 2026-08-05 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NVCT | SELL | 2024-11-07 | 2024-11-08 | $8.16 | $22K | -55.1% | -57.4% | -35.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.